Inventor · disambiguated record
David Bellovin
Also filed as: BELLOVIN DAVID · BELLOVIN DAVID I
13 granted patents·10 pending applications·57 citations·filing 2012–2025
89Inventor score
Files withFIVE PRIME THERAPEUTICS INC20ATTOVIA THERAPEUTICS INC1FELSHER DEAN W1ZAI LAB SHANGHAI CO LTD1
Top patents by PatentIndex Score
23 records- 0195US9765147B2Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Sep 19, 2017·25 cites·31 claims
- 0292US10221244B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·10 cites·31 claims
- 0391US11306144B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Apr 19, 2022·6 cites·45 claims
- 0490US11814431B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Nov 14, 2023·3 cites·48 claims
- 0588US10618967B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Apr 14, 2020·5 cites·31 claims
- 0686US10273281B2CD80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Apr 30, 2019·7 cites·40 claims
- 0781US2024043542A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0881US2023212299A1Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0978US12365719B2CD80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2022·Granted Jul 22, 2025·0 cites·18 claims
- 1072US2023013293A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1171US11566076B2Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancersFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 31, 2023·0 cites·25 claims
- 1271US11098103B2CD80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Aug 24, 2021·0 cites·8 claims
- 1369US9775881B2Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECDFIVE PRIME THERAPEUTICS INC·Filed 2014·Granted Oct 3, 2017·1 cites·19 claims
- 1465US2023192870A1Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1562US11559583B2Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 24, 2023·0 cites·18 claims
- 1659US11421034B2Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancerFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 23, 2022·0 cites·15 claims
- 1758US2019194288A1Cd80 extracellular domain polypeptides and their use in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1851US2018085472A1Combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 1948US2025034266A1Ccr8 antigen binding unit and uses thereofZAI LAB SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 2047US12509510B2IL31-binding polypeptides and uses thereofATTOVIA THERAPEUTICS INC·Filed 2025·Granted Dec 30, 2025·0 cites·19 claims
- 2140US2014121130A1Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasisFELSHER DEAN W·Filed 2012·Application pending·0 cites
- 2237US2020031944A1Combination therapy for cancer using anti-gitr antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2336US2018016555A1Slamf1 antagonists and uses thereofFIVE PRIME THERAPEUTICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Bellovin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →